MedPath

Anlotinib

Generic Name
Anlotinib
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C23H22FN3O3
CAS Number
1058156-90-3
Unique Ingredient Identifier
GKF8S4C432
Background

Anlotinib has been investigated for the treatment of Non-small Cell Lung Cancer and Metastatic Colorectal Cancer.

Indication

用于治疗非小细胞肺癌、结直肠癌、肾癌、软组织肉瘤、甲状腺癌、胃癌等。

用于无法手术的局部晚期或转移性甲状腺髓样癌患者的治疗。

Associated Conditions
-
Associated Therapies
-

Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202)

Phase 2
Completed
Conditions
Small Cell Lung Cancer
Interventions
Drug: Placebo
Drug: Anlotinib
First Posted Date
2017-02-23
Last Posted Date
2019-05-16
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Target Recruit Count
120
Registration Number
NCT03059797
Locations
🇨🇳

The 307th Hospital of Chinese People's Liberation Army, Beijing, Beijing, China

🇨🇳

Guangdong General Hospital, Guangzhou, Guangdong, China

🇨🇳

Hunan Cancer Hospital, Changsha, Hunan, China

and more 9 locations

A Phase I Study of Anlotinib on Pharmacokinetics to Assess the Effect of High Fat Diet in Advanced Cancer Patients

Phase 1
Completed
Conditions
Advanced Cancer
Interventions
First Posted Date
2016-07-07
Last Posted Date
2019-05-22
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Target Recruit Count
22
Registration Number
NCT02825563
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

A Study of Anlotinib in Patients With Hepatocellular Carcinoma

Phase 2
Conditions
Hepatocellular Carcinoma
Interventions
First Posted Date
2016-06-22
Last Posted Date
2016-09-07
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Target Recruit Count
60
Registration Number
NCT02809534
Locations
🇨🇳

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

A Phase I Additional Study of Anlotinib on Tolerance and Pharmacokinetics

Phase 1
Conditions
Cancer
Interventions
First Posted Date
2016-04-27
Last Posted Date
2017-09-18
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Target Recruit Count
16
Registration Number
NCT02752516
Locations
🇨🇳

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)

Phase 2
Completed
Conditions
Esophageal Squamous Cell Carcinoma
Interventions
Drug: Placebo
Drug: Anlotinib
First Posted Date
2016-01-07
Last Posted Date
2019-06-05
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Target Recruit Count
164
Registration Number
NCT02649361
Locations
🇨🇳

Fujian Medical University Union Hospital, Fuzhou, Fujian, China

🇨🇳

The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China

🇨🇳

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

and more 15 locations

Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032)

Phase 2
Conditions
Differentiated Thyroid Cancer
Interventions
Drug: Placebo
Drug: Anlotinib
First Posted Date
2015-10-26
Last Posted Date
2019-05-21
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Target Recruit Count
113
Registration Number
NCT02586337
Locations
🇨🇳

Jiangsu province tumor hospital, Nanjing, Jiangsu, China

🇨🇳

Beijing Tongren Hospital, Beijing, Beijing, China

🇨🇳

Peking Union Medical College Hospital, Beijing, Beijing, China

and more 16 locations

Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031)

Phase 2
Completed
Conditions
Medullary Thyroid Carcinoma
Interventions
Drug: Placebo
Drug: Anlotinib
First Posted Date
2015-10-26
Last Posted Date
2019-05-21
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Target Recruit Count
91
Registration Number
NCT02586350
Locations
🇨🇳

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

🇨🇳

Harbin medical university affiliated tumor hospital, Harbin, Heilongjiang, China

🇨🇳

Peking Union Medical College Hospital, Beijing, Beijing, China

and more 16 locations

Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)

Phase 2
Conditions
Gastric Cancer
Interventions
Drug: Placebo
Drug: Anlotinib
First Posted Date
2015-06-03
Last Posted Date
2017-12-29
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Target Recruit Count
378
Registration Number
NCT02461407
Locations
🇨🇳

The First Affiliated Hospital, Anhui Medical University, Hefei, Anhui, China

🇨🇳

The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China

🇨🇳

Fourth Hospital of Hebei Medical University Tumor Hospital of Hebei Province, Shijiazhuang, Hebei, China

and more 35 locations

Study of Anlotinib in Patients With Soft Tissue Sarcoma(STS)(ALTER0203)

Phase 2
Conditions
Soft Tissue Sarcoma
Interventions
Drug: Placebo
Drug: Anlotinib
First Posted Date
2015-05-20
Last Posted Date
2017-04-25
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Target Recruit Count
233
Registration Number
NCT02449343
Locations
🇨🇳

Gansu Cancer Hospital, Lanzhou, Gansu, China

🇨🇳

Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China

🇨🇳

Guangxi medical university affiliated tumor hospital, Nanning, Guangxi, China

and more 22 locations

Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer(ALTER0303)

Phase 2
Completed
Conditions
Non-small Cell Lung Cancer
Interventions
Drug: Placebo
Drug: Anlotinib
First Posted Date
2015-03-17
Last Posted Date
2017-09-18
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Target Recruit Count
439
Registration Number
NCT02388919
Locations
🇨🇳

Xinqiao Hospital, Chongqing, Chongqing, China

🇨🇳

Gansu Provincial People 's Hospital, Lanzhou, Gansu, China

🇨🇳

First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China

and more 37 locations
© Copyright 2025. All Rights Reserved by MedPath